Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective.
J Med Econ
; 27(1): 952-962, 2024.
Article
em En
| MEDLINE
| ID: mdl-39015093
ABSTRACT
OBJECTIVES:
Biosimilars improve patient access by providing cost-effective treatment options. This study assessed the potential for savings and expanded patient access with increased use of two biosimilar disease modifying anti-rheumatic drugs (DMARDs) (a) approved adalimumab biosimilars and (b) the first tocilizumab biosimilar, representing an established biosimilar field and a recent biosimilar entrant in France, Germany, Italy, Spain, and the United Kingdom (UK).METHODS:
Separate ex-ante analyses were conducted for each country, parameterized using country-specific list prices, unit volumes annually, and market shares for each therapy. Discounting scenarios of 10%, 20%, and 30% were tested for tocilizumab. Outputs included direct cost-savings associated with drug acquisition or the incremental number of patients that could be treated if savings were redirected. Two biosimilar conversion scenarios were tested.RESULTS:
Savings associated with a 100% conversion to adalimumab biosimilar ranged from 10.5 to 187 million (UK and Germany, respectively), or an additional 1,096 to 19,454 patients that could be treated using the cost-savings. Introduction of a tocilizumab biosimilar provided savings up to 29.3 million in the most conservative scenario. Exclusive use of tocilizumab biosimilars (at a 30% discount) could increase savings to 28.8 to 113 million or expand access to an additional 43% of existing tocilizumab users across countries.CONCLUSION:
This study demonstrates the benefits that can be realized through increased biosimilar adoption, not only in an untapped tocilizumab market, but also through incremental increases in well-established markets such as adalimumab. As healthcare budgets continue to face downwards pressure globally, strategies to increase biosimilar market share could prove useful to help manage financial constraints.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Redução de Custos
/
Antirreumáticos
/
Anticorpos Monoclonais Humanizados
/
Medicamentos Biossimilares
/
Adalimumab
Limite:
Humans
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article